|
Monday, March 9, 2009 - 4:30 PM
Convention Center Auditorium
Todd R. Golub, M.D.
Click the button above to add this event to your Itinerary Planner...
 Todd Golub is a founding member of the Broad Institute, collaboration between the Massachusetts Institute of Technology and Harvard University, and serves as director of its cancer program. He is a world leader in the application of genomic tools to study and classify neoplastic diseases. Together with his team of investigators, his work focuses on characterizing the molecular events associated with specific tumor types and identifying potential therapeutic targets. Among others, he has made seminal discoveries in the molecular basis of childhood leukemia and pioneered the use of high throughput genomic approaches to cancer biology. He is a key member of the Cancer Genome Atlas Research Network. At the present time he is studying microRNA expression profiles in various tumors as well as developing technologies to perform high throughput gene expression profiling on fixed tissues, as evidenced by recent publications in the Proceedings of the National Academy of Science and the New England Journal of Medicine.
Dr. Golub received his bachelor’s degree from Carleton College in 1985 and his medical doctorate from the University of Chicago Pritzker School of Medicine in 1989. He completed a residency in Pediatrics followed by a fellowship in pediatric hematology/oncology at Children’s Hospital and Dana Farber Institute. In 1994 he joined the medical staff at the Harvard Medical School in the Department of Pediatrics and in 1997 he joined the Whitehead Institute/MIT Center of Genome Research as director of is cancer program. At the present time he is the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, associate professor of pediatrics at the Harvard Medical School and a Howard Hughes Medical Institute investigator. Todd is the recipient of multiple awards including Discover Magazine’s Inventor of the Year (health category), the Daland Prize of the American Philosophical Society in 2001, the Outstanding Achievement Award of the American Association for Cancer Research in 2002, the Paul Mark’s Prize for Cancer Research in 2007 and the E. Mead Johnson Award in 2008.
|
|
|
